Kingworld Medicines Group Limited (KINGWORLD) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited for the period ended 30 April 2026. The filing confirms stability across the company’s share structure during the month.

At month-end, authorised share capital stood unchanged at 10.00 billion ordinary shares with a par value of HKD 0.10 each, representing total authorised capital of HKD 1.00 billion.

Issued share capital also remained steady: 622.50 million ordinary shares were outstanding, with no treasury shares held. There were no movements in issued or treasury shares during April—no share issuances, buy-backs, options, warrants, convertibles, or other equity arrangements were recorded.

KINGWORLD affirmed compliance with the Main Board’s minimum public-float requirement of 25% of issued shares, indicating adequate free-float levels for the month-end.

The return was authorised and submitted by Director Zhou Xuhua on 4 May 2026.